NMS·Healthcare·$120M·#164 / 520 in Healthcare
APYX Apyx Medical Corporation
57SPECULATIVE
CATEGORY BREAKDOWN
GROWTH16
QUALITY61
STABILITY67
VALUATION94
GOVERNANCE60
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+9.9%
16
> 50% strong
Gross Margin
Revenue retained after direct costs
62.5%
89
> 50% strong
Cash Runway
Months of cash at current burn rate
48 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
270.6%
0
< 25% strong
Price / Sales
Market cap relative to trailing revenue
2.3x
94
< 3x strong
Rule of 40
Growth rate plus operating margin
-2
18
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
13.3%
72
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+10.7%
38
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE APYX WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when APYX's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.